These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33243618)

  • 41. Biosimilars are coming: ready or not.
    Zalcberg J
    Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta-analysis in anorectal medicine.
    Li Y; Mei Z; Shi L; Wan Y; Zhou X; Zeng T; Liu Y; Yang JY; Shi Z
    Int Wound J; 2024 Jan; 21(1):e14638. PubMed ID: 38272807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
    Pham C; Niu F; Delate T; Buchschacher GL; Li Y; Ekinci E; Le K; Hui RL
    BioDrugs; 2023 Nov; 37(6):891-899. PubMed ID: 37747629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar.
    Reinisch W; Cohen S; Ramchandani M; Khraishi M; Liu J; Chow V; Franklin J; Colombel JF
    Adv Ther; 2022 Jan; 39(1):44-57. PubMed ID: 34757601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars: Extrapolation for oncology.
    Curigliano G; O'Connor DP; Rosenberg JA; Jacobs I
    Crit Rev Oncol Hematol; 2016 Aug; 104():131-7. PubMed ID: 27354233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biosimilars-Emerging Role in Nephrology.
    Wish JB
    Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biosimilars in Dermatology - theory becomes reality.
    Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.
    Guillen E; Ekman N; Barry S; Weise M; Wolff-Holz E
    Clin Pharmacol Ther; 2023 Jan; 113(1):108-123. PubMed ID: 36546547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective.
    Cohen HP; Turner M; McCabe D; Woollett GR
    BioDrugs; 2023 Sep; 37(5):583-593. PubMed ID: 37542600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.